July 2026 Research Update

Across these reports, autoimmune hemolytic anemia (AIHA) appeared soon after a clear trigger, either an infection or a newly started medicine. The shared pattern was lab-confirmed immune hemolysis (often with a positive direct antiglobulin test) plus clinical anemia symptoms, followed by improvement once the suspected trigger was addressed. Because all evidence here comes from single-patient case reports, it shows what can happen but cannot estimate how often it occurs or who is at risk. [1] [2] [3] [4] [5]

Several infections were reported alongside AIHA. One 23-year-old man developed severe hemolysis during leptospirosis (confirmed by antibody testing) and improved after antibiotics and high-dose corticosteroids, with hemoglobin stabilizing and symptoms resolving. [1]

A 22-year-old woman developed cold-type AIHA after Mycoplasma pneumoniae pneumonia, with complement-positive testing and high cold agglutinin levels, and she also had painless thyroiditis and a deep vein thrombosis confirmed on ultrasound. She improved with cold avoidance and apixaban. [4]

In a 28-year-old man with Plasmodium vivax malaria, immune-mediated hemolysis testing supported AIHA alongside low platelets, and he recovered after malaria treatment plus compatible blood transfusions without corticosteroids. By day 5 his blood counts improved and the malaria smear became negative. [5]

Two reports focused on medicines as potential triggers. An 83-year-old woman developed rapid drug-induced immune hemolytic anemia together with immune thrombocytopenia after starting piperacillin-tazobactam for pneumonia; testing detected piperacillin-dependent antibodies, and she recovered after stopping the drug and receiving supportive care (including transfusions, intravenous immune globulin, and corticosteroids), with no recurrence reported over one year. [3]

A 31-year-old man with ulcerative colitis developed immune-mediated hemolytic anemia after starting etrasimod, with an IgG-positive direct antiglobulin test; hemolysis continued even after the drug was stopped but resolved after high-dose prednisone, supporting a possible drug-related immune mechanism in this single case. The report also noted that the link cannot be proven from one patient. [2]

For patients and caregivers, this set of papers mainly adds background on situations where AIHA has been reported: certain infections and certain medicines, sometimes with other immune problems (like low platelets) or clotting events. The reports also show that recovery was possible in each described patient, but the details varied a lot (type of AIHA, other organ issues, and supportive care used). What remains uncertain is how common these triggers are in real-world AIHA and which personal or medical factors make a trigger more likely, because case reports cannot answer those questions.

Across these papers, treatment-resistant autoimmune hemolytic anemia (AIHA) was approached in different ways depending on the situation: ongoing hard-to-control disease, AIHA occurring alongside another blood condition, or a sudden drug-triggered hemolysis crisis. The overall pattern was rapid improvement after treatment in the reports, but the level of certainty varies because one study was small and the others were single-patient case reports. [6] [7] [8]

In a retrospective cohort of 22 adults with treatment-refractory autoimmune cytopenias, a combination of daratumumab, rituximab, and glucocorticoids produced quick responses that often lasted through follow-up. In the AIHA subgroup, the reported overall response rate was 80.0% with a complete response rate of 60.0%, and the median time to response across the whole group was 7 days. Side effects were reported in 36.4% of patients and included infections and rash, which resolved. [6]

One case report described a 57-year-old woman with a severe ceftriaxone-induced immune hemolytic crisis who was treated with a whole blood exchange and lymphoplasmapheresis combined transfusion (WLCT) plus glucocorticoids, followed by a second-line double plasma molecular adsorption system (DPMAS). The report described rapid reduction in hemolysis, a change to a negative direct Coombs test after treatment, discharge after 10 days, and stable condition at 3 months. Because this was a single patient, it cannot show how often this approach works or how safe it is in general. [8]

Another single-patient report involved a child with non-transfusion-dependent thalassemia complicated by AIHA who had a significant clinical response to thalidomide, alongside a focused literature review on thalidomide use in thalassemia populations with AIHA. The paper supports that this is an area of interest, but it does not provide the kind of evidence needed to predict results for most patients with AIHA. [7]

For patients and caregivers, these studies mainly add background about approaches clinicians have tried when standard AIHA treatments have not worked, or when hemolysis is triggered by a specific drug or occurs with another blood disorder. The clearest data here come from a small adult cohort using a daratumumab plus rituximab and glucocorticoid combination, while the other two papers describe individual patients and therefore cannot estimate typical benefits or risks. What remains uncertain is how well these strategies work across different AIHA types, how long benefits last in broader use, and how safety compares in larger, prospective studies. [6] [7] [8]

Across this month’s research in autoimmune hemolytic anemia (AIHA), one clinical study suggested that adding an extra lab test that checks red blood cell breakdown (a hemolysis test) to guide which donor blood to transfuse may lead to better short-term lab results after transfusion than a standard blood-matching method. Because it was a retrospective, single-hospital comparison, it is not yet clear how well these results apply to other hospitals or patient groups. [9]

In this study, both approaches improved blood measures after transfusion, but the hemolysis test-guided group had higher red blood cell count and hemoglobin, and lower markers linked to red blood cell breakdown compared with the standard matching group. The study also reported better clotting-related lab results in the hemolysis test-guided group. [9]

The researchers also reported a higher overall response rate with the hemolysis test-guided strategy (86.0% vs 66.7%). The report did not describe safety outcomes in the summary provided, so it is not possible to tell from this paper summary whether the two strategies differed in transfusion reactions or other side effects. [9]

For patients and caregivers, this study mainly adds background about how different lab approaches to selecting donor blood might affect short-term lab results after a transfusion in AIHA. The evidence is limited to one center and a retrospective design, and it does not clarify which specific AIHA situations benefit most or whether outcomes like symptoms, transfusion reactions, or longer-term control differ between strategies.

Across this paper, the main message was that cold agglutinin disease (CAD) can be easier to recognize and confirm when laboratories and clinics use a consistent set of tests and handle blood samples in a consistent way. The framework particularly emphasized complement-related results on the direct antiglobulin (Coombs) test and the need to keep samples warm during processing, because pre-test handling can affect results. [10]

In a two-round structured expert process, 27 specialists agreed on 37 diagnostic statements covering when to suspect CAD and which tests to order. Key elements included a direct antiglobulin test that is positive for C3d (a complement marker) and detecting cold agglutinins in the serum, along with guidance on cold agglutinin titration. [10]

The same consensus placed strong weight on pre-analytical handling, recommending that samples be maintained at 37 degrees C to help avoid misleading results. It also included related practical areas tied to diagnosis, such as transfusion management and immune-hematologic follow-up, but it did not test the framework in patients. [10]

For patients and caregivers, this work mainly matters as background that may explain why CAD testing can involve specific blood tests and special handling of blood samples to keep them warm. Because this was expert consensus rather than a clinical trial, it does not show how often the framework improves accuracy in real-world care, and it does not replace individualized clinical judgment.

Across the papers, a consistent pattern was that autoimmune hemolytic anemia (AIHA) is sometimes part of a wider immune picture rather than a stand-alone blood problem. In a large pediatric cohort, many children had Evans syndrome, other autoimmune diseases, or inborn errors of immunity, and immune test abnormalities were common. [11]

In the multicenter study of 399 children, relapse of AIHA was more common in those who had Evans syndrome, inborn errors of immunity, or other autoimmune diagnoses, and deaths occurred only in children with a secondary (underlying) diagnosis. Many children needed more than one treatment approach during their first episode, and a substantial minority were still on treatment years later, showing that long-term disease activity can occur. [11]

A smaller prospective study followed children who had persistent antiphospholipid antibodies and blood count problems to see who later developed antiphospholipid syndrome and/or lupus. About a quarter progressed over time, and having Evans syndrome was the clearest sign of higher risk, while isolated low platelets had the lowest risk and AIHA fell in between without being an independent predictor. [12]

Several single-patient reports illustrated how AIHA can overlap with other immune conditions and sometimes other organs. One newborn had fetal-onset Evans syndrome (AIHA plus low platelets) from the baby s own antibodies and later developed a liver inflammation called giant cell hepatitis, with only partial response to immune treatments and no clear genetic cause found. [13]

Other case reports described Evans syndrome occurring with lupus in special situations. One pregnant adult presented with Evans syndrome and was later diagnosed with systemic lupus erythematosus after delivery; her blood counts improved during the acute episode and later normalized with lupus-directed treatment. [14]

Another child developed a lupus-like autoimmune syndrome years after stem cell transplant for thalassemia, in the context of chronic graft-versus-host disease and mixed donor-recipient immune cells; symptoms and blood markers improved quickly after immune-suppressing medicines. This report highlights that immune system changes after transplant can be linked to lupus-like illness that includes low blood counts. [15]

For patients and caregivers, this set of studies mainly adds context: AIHA, especially in children, may come with other immune diagnoses (like Evans syndrome, lupus, antiphospholipid antibodies, or rare immune system disorders), and those overlaps were tied to more relapse in the large pediatric study. The strongest evidence here comes from the multicenter pediatric cohort and the smaller prospective follow-up study; the case reports show what can happen in individual situations (including pregnancy, newborn onset, post-transplant immune changes, and liver involvement) but cannot predict what will happen for most people.

Across this months papers, the long-term impact of autoimmune hemolytic anemia (AIHA) looked different depending on the situation: in chronic lymphocytic leukemia (CLL) it tracked with worse overall outcomes, while a separate report highlighted that long-lasting hemolysis can sometimes strain the liver and bile system. A lab-based blood smear study also supported that certain red blood cell shape changes tend to be seen more when anemia is more severe, although it did not focus on long-term complications directly. [16] [17] [18]

In a retrospective cohort of 1,404 people with CLL, AIHA occurred in 10.4% and was most often warm-antibody AIHA. People with CLL who developed AIHA had worse outcomes overall, but this negative effect was smaller in more recent eras where targeted therapies were used. The study also reported differences in gene changes by AIHA type, with DNMT3A mutations more frequent in AIHA overall and MYD88 mutations more common in cold-antibody AIHA. [16]

A single-patient case report described a 73-year-old man with warm AIHA who developed severe jaundice due to secondary cholestasis from chronic hemolysis. Imaging raised concern for blockage and possible cancer, but an endoscopic procedure removed multiple black pigment stones (linked to hemolysis) and testing did not show cancer. This report illustrates that, in some situations, long-standing hemolysis can contribute to bile flow problems and can mimic more serious liver or bile duct disease. [17]

In an observational study of 251 peripheral blood smears across many blood disorders (including AIHA), higher counts of fish-shaped red blood cells and pincer cells were linked to lower hemoglobin across the full set of conditions studied. This supports the idea that certain red blood cell shape changes may reflect more severe anemia, but the study did not establish what these shapes mean for future complications or outcomes in AIHA specifically. [18]

For patients and caregivers, this set of studies mainly adds context about longer-term risks rather than giving direct, individualized forecasts. The strongest evidence here comes from people with CLL, where AIHA was tied to worse overall outcomes but seemed less strongly harmful in the era of targeted CLL treatments, suggesting that the underlying disease and its therapies can influence the long-term picture. The case report is important as background awareness that chronic hemolysis can sometimes affect the liver and bile ducts and even resemble cancer on scans, but it describes one person and may not be common. What remains uncertain is how often bile-related complications happen in AIHA more broadly, and whether the blood-smear shape changes can predict specific long-term complications in AIHA.

Across these papers, the main message is that autoimmune hemolytic anemia can create extra challenges in certain situations (like procedures involving blood handling), and outcomes may depend on added stressors such as cold exposure or infection. The strongest evidence here is limited, because one paper is a single-patient case report and the other is a short-term animal cohort study.

In one adult case report, a man with cold agglutinin disease (a form of hemolysis triggered by cold) underwent autologous stem cell collection and transplant without cold-related complications when the care team used multiple warming and temperature-control steps during collection, processing, and infusion, alongside complement-blocking therapy. The report described successful cell collection and engraftment, and no recurrence of hemolysis during follow-up, but it reflects one person and may not apply to others. [19]

In a prospective veterinary cohort of 55 dogs with immune-mediated hemolytic anemia followed for 60 days, dogs with a specific tick-borne parasite co-infection (Babesia gibsoni) had a higher risk of death than dogs without that infection. This suggests that, at least in that animal setting, an added infection can meaningfully worsen short-term outlook in immune-driven hemolysis. [20]

For patients and caregivers, these studies mainly provide background on why care planning can look different when autoimmune hemolytic anemia overlaps with special circumstances like cold-triggered hemolysis during blood-handling procedures. The human evidence in this set comes from one detailed case report, so it shows what was feasible for one person rather than defining what to expect. The animal study raises the general idea that co-existing infections may affect outcomes in immune-related hemolysis, but how that applies to human autoimmune hemolytic anemia remains uncertain based on these papers alone.